These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 24627419)

  • 1. Changes in mipomersen dosing regimen provide similar exposure with improved tolerability in randomized placebo-controlled study of healthy volunteers.
    Flaim JD; Grundy JS; Baker BF; McGowan MP; Kastelein JJ
    J Am Heart Assoc; 2014 Mar; 3(2):e000560. PubMed ID: 24627419
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Apolipoprotein B synthesis inhibition with mipomersen in heterozygous familial hypercholesterolemia: results of a randomized, double-blind, placebo-controlled trial to assess efficacy and safety as add-on therapy in patients with coronary artery disease.
    Stein EA; Dufour R; Gagne C; Gaudet D; East C; Donovan JM; Chin W; Tribble DL; McGowan M
    Circulation; 2012 Nov; 126(19):2283-92. PubMed ID: 23060426
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term efficacy and safety of mipomersen in patients with familial hypercholesterolaemia: 2-year interim results of an open-label extension.
    Santos RD; Duell PB; East C; Guyton JR; Moriarty PM; Chin W; Mittleman RS
    Eur Heart J; 2015 Mar; 36(9):566-75. PubMed ID: 24366918
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Randomized, placebo-controlled trial of mipomersen in patients with severe hypercholesterolemia receiving maximally tolerated lipid-lowering therapy.
    McGowan MP; Tardif JC; Ceska R; Burgess LJ; Soran H; Gouni-Berthold I; Wagener G; Chasan-Taber S
    PLoS One; 2012; 7(11):e49006. PubMed ID: 23152839
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mipomersen, an apolipoprotein B synthesis inhibitor, reduces atherogenic lipoproteins in patients with severe hypercholesterolemia at high cardiovascular risk: a randomized, double-blind, placebo-controlled trial.
    Thomas GS; Cromwell WC; Ali S; Chin W; Flaim JD; Davidson M
    J Am Coll Cardiol; 2013 Dec; 62(23):2178-84. PubMed ID: 24013058
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and efficacy of mipomersen in patients with heterozygous familial hypercholesterolemia.
    Reeskamp LF; Kastelein JJP; Moriarty PM; Duell PB; Catapano AL; Santos RD; Ballantyne CM
    Atherosclerosis; 2019 Jan; 280():109-117. PubMed ID: 30500603
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of apolipoprotein B synthesis inhibition in subjects with mild-to-moderate hyperlipidaemia.
    Akdim F; Tribble DL; Flaim JD; Yu R; Su J; Geary RS; Baker BF; Fuhr R; Wedel MK; Kastelein JJ
    Eur Heart J; 2011 Nov; 32(21):2650-9. PubMed ID: 21593041
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial.
    Raal FJ; Santos RD; Blom DJ; Marais AD; Charng MJ; Cromwell WC; Lachmann RH; Gaudet D; Tan JL; Chasan-Taber S; Tribble DL; Flaim JD; Crooke ST
    Lancet; 2010 Mar; 375(9719):998-1006. PubMed ID: 20227758
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mipomersen, an apolipoprotein B synthesis inhibitor, lowers low-density lipoprotein cholesterol in high-risk statin-intolerant patients: a randomized, double-blind, placebo-controlled trial.
    Visser ME; Wagener G; Baker BF; Geary RS; Donovan JM; Beuers UH; Nederveen AJ; Verheij J; Trip MD; Basart DC; Kastelein JJ; Stroes ES
    Eur Heart J; 2012 May; 33(9):1142-9. PubMed ID: 22507979
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of mipomersen, an antisense inhibitor of apolipoprotein B, in hypercholesterolemic subjects receiving stable statin therapy.
    Akdim F; Stroes ES; Sijbrands EJ; Tribble DL; Trip MD; Jukema JW; Flaim JD; Su J; Yu R; Baker BF; Wedel MK; Kastelein JJ
    J Am Coll Cardiol; 2010 Apr; 55(15):1611-8. PubMed ID: 20378080
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of mipomersen, an apolipoprotein B synthesis inhibitor, on low-density lipoprotein cholesterol in patients with familial hypercholesterolemia.
    Akdim F; Visser ME; Tribble DL; Baker BF; Stroes ES; Yu R; Flaim JD; Su J; Stein EA; Kastelein JJ
    Am J Cardiol; 2010 May; 105(10):1413-9. PubMed ID: 20451687
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of mipomersen on LDL-cholesterol in patients with severe LDL-hypercholesterolaemia and atherosclerosis treated by lipoprotein apheresis (The MICA-Study).
    Waldmann E; Vogt A; Crispin A; Altenhofer J; Riks I; Parhofer KG
    Atherosclerosis; 2017 Apr; 259():20-25. PubMed ID: 28279833
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Therapeutic potential of mipomersen in the management of familial hypercholesterolaemia.
    Gelsinger C; Steinhagen-Thiessen E; Kassner U
    Drugs; 2012 Jul; 72(11):1445-55. PubMed ID: 22799743
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lack of pharmacokinetic interaction of mipomersen sodium (ISIS 301012), a 2'-O-methoxyethyl modified antisense oligonucleotide targeting apolipoprotein B-100 messenger RNA, with simvastatin and ezetimibe.
    Yu RZ; Geary RS; Flaim JD; Riley GC; Tribble DL; vanVliet AA; Wedel MK
    Clin Pharmacokinet; 2009; 48(1):39-50. PubMed ID: 19071883
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pediatric experience with mipomersen as adjunctive therapy for homozygous familial hypercholesterolemia.
    Raal FJ; Braamskamp MJ; Selvey SL; Sensinger CH; Kastelein JJ
    J Clin Lipidol; 2016; 10(4):860-869. PubMed ID: 27578117
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mipomersen and other therapies for the treatment of severe familial hypercholesterolemia.
    Bell DA; Hooper AJ; Watts GF; Burnett JR
    Vasc Health Risk Manag; 2012; 8():651-9. PubMed ID: 23226021
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and Safety of Mipomersen: A Systematic Review and Meta-Analysis of Randomized Clinical Trials.
    Fogacci F; Ferri N; Toth PP; Ruscica M; Corsini A; Cicero AFG
    Drugs; 2019 May; 79(7):751-766. PubMed ID: 30989634
    [TBL] [Abstract][Full Text] [Related]  

  • 18. N-acetyl galactosamine-conjugated antisense drug to APOC3 mRNA, triglycerides and atherogenic lipoprotein levels.
    Alexander VJ; Xia S; Hurh E; Hughes SG; O'Dea L; Geary RS; Witztum JL; Tsimikas S
    Eur Heart J; 2019 Sep; 40(33):2785-2796. PubMed ID: 31329855
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mipomersen is a promising therapy in the management of hypercholesterolemia: a meta-analysis of randomized controlled trials.
    Li N; Li Q; Tian XQ; Qian HY; Yang YJ
    Am J Cardiovasc Drugs; 2014 Oct; 14(5):367-76. PubMed ID: 25027352
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antisense therapy targeting apolipoprotein(a): a randomised, double-blind, placebo-controlled phase 1 study.
    Tsimikas S; Viney NJ; Hughes SG; Singleton W; Graham MJ; Baker BF; Burkey JL; Yang Q; Marcovina SM; Geary RS; Crooke RM; Witztum JL
    Lancet; 2015 Oct; 386(10002):1472-83. PubMed ID: 26210642
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.